{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:40:04Z","timestamp":1786441204294,"version":"build-2736575974"},"reference-count":147,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Influenza remains a persistent global health threat, accounting for an estimated one billion infections and 350,000\u2013600,000 deaths worldwide annually. Beyond substantial mortality and morbidity, influenza imposes major socio-economic costs through healthcare utilisation and productivity losses, amounting to tens of billions of dollars each year. Current seasonal vaccination strategies are constrained by rapid antigenic evolution, which necessitates frequent vaccine reformulation and contributes to suboptimal vaccine efficacy across seasons. These drawbacks highlight the need for a universal influenza vaccine (UIV) that protects against all seasonal and potential pandemic influenza strains via a single dose. This review evaluates the feasibility of a UIV as an alternative to a seasonal influenza vaccine (SIV) by consolidating evidence from current UIV candidates in preclinical and clinical development across a diverse range of platforms and target epitopes. Preclinical studies and clinical trials have demonstrated the safety and tolerability of multiple candidates, as well as their ability to elicit broadly cross-reactive immune responses. However, several challenges remain regarding the long-term efficacy of these vaccines. In particular, pre-existing host immunity can shape subsequent vaccine responses, with immune imprinting introducing biases toward previously encountered influenza strains, potentially reducing vaccine effectiveness. In addition, the genetic plasticity of influenza viruses, driven by ongoing mutations and genetic reassortment, raises concerns about the ability of a single vaccine formulation to maintain broad and durable protection. Overall, several UIV candidates have shown promising early results. Although ecological and immunological barriers remain, a UIV could become a viable alternative to, or eventual replacement, for SIVs.<\/jats:p>","DOI":"10.3390\/antib15040075","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:11:16Z","timestamp":1786439476000},"page":"75","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the Development of a Universal Influenza Vaccine"],"prefix":"10.3390","volume":"15","author":[{"given":"Preanka","family":"Mudaly","sequence":"first","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8643-1701","authenticated-orcid":false,"given":"Max","family":"Lee","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Bhatta","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Thompson","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza Virus: Dealing with a Drifting and Shifting Pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wang, W.-C., Sayedahmed, E.E., Sambhara, S., and Mittal, S.K. (2022). Progress towards the Development of a Universal Influenza Vaccine. Viruses, 14.","DOI":"10.3390\/v14081684"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","article-title":"Influenza vaccine: The challenge of antigenic drift","volume":"25","author":"Carrat","year":"2007","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature14460","article-title":"Global circulation patterns of seasonal influenza viruses vary with antigenic drift","volume":"523","author":"Bedford","year":"2015","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nature06945","article-title":"The genomic and epidemiological dynamics of human influenza A virus","volume":"453","author":"Rambaut","year":"2008","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2019.01.002","article-title":"Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus","volume":"163","author":"Kim","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/jix591","article-title":"One Step Forward in the Road Toward a Universal Influenza Vaccine","volume":"217","author":"Ramilo","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nguyen, Q.T., and Choi, Y.K. (2021). Targeting Antigens for Universal Influenza Vaccine Development. Viruses, 13.","DOI":"10.3390\/v13060973"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01580-15","DOI":"10.1128\/mBio.01580-15","article-title":"Is It Possible? A Different Approach to Creating a Universal Influenza Vaccine","volume":"6","year":"2015","journal-title":"mBio"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","article-title":"The Pathway to a Universal Influenza Vaccine","volume":"47","author":"Paules","year":"2017","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.tim.2013.04.003","article-title":"The prospects and challenges of universal vaccines for influenza","volume":"21","author":"Subbarao","year":"2013","journal-title":"Trends Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Saunders-Hastings, P., and Krewski, D. (2016). Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission. Pathogens, 5.","DOI":"10.3390\/pathogens5040066"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/infdis\/jiz043","article-title":"Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine","volume":"219","author":"Crank","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.coviro.2020.02.003","article-title":"Tracking progress in universal influenza vaccine development","volume":"40","author":"Ostrowsky","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40265-024-02083-8","article-title":"Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine","volume":"84","author":"Cowling","year":"2024","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1586\/erv.12.73","article-title":"Universal influenza vaccine: The holy grail?","volume":"11","author":"Shaw","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sun, W., Luo, T., Liu, W., and Li, J. (2020). Progress in the Development of Universal Influenza Vaccines. Viruses, 12.","DOI":"10.3390\/v12091033"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/infdis\/jiz004","article-title":"Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins","volume":"219","author":"Ross","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"a028852","DOI":"10.1101\/cshperspect.a028852","article-title":"Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination","volume":"10","author":"Angeletti","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1126\/science.aba2754","article-title":"Toward a universal flu vaccine","volume":"367","author":"Herold","year":"2020","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.coviro.2016.03.002","article-title":"Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine","volume":"17","author":"Cho","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bolton, J.S., Klim, H., Wellens, J., Edmans, M., Obolski, U., and Thompson, C.P. (2021). An Antigenic Thrift-Based Approach to Influenza Vaccine Design. Vaccines, 9.","DOI":"10.3390\/vaccines9060657"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1038\/s41467-018-06228-8","article-title":"A naturally protective epitope of limited variability as an influenza vaccine target","volume":"9","author":"Thompson","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sangesland, M., and Lingwood, D. (2021). Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for \u201cUniversal\u201d Influenza Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9020125"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"a029496","DOI":"10.1101\/cshperspect.a029496","article-title":"Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine","volume":"10","author":"Crowe","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"a028845","DOI":"10.1101\/cshperspect.a028845","article-title":"Is It Possible to Develop a \u201cUniversal\u201d Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine","volume":"10","author":"Krammer","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/vaccines3020239","article-title":"Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head","volume":"3","author":"Wiersma","year":"2015","journal-title":"Vaccines"},{"key":"ref_30","first-page":"21","article-title":"Biomimetic nanoparticles as universal influenza vaccine","volume":"1","author":"Wang","year":"2020","journal-title":"Smart Mater. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11684-020-0764-y","article-title":"Recent advances in \u201cuniversal\u201d influenza virus antibodies: The rise of a hidden trimeric interface in hemagglutinin globular head","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"546274","DOI":"10.1155\/2014\/546274","article-title":"Protective Immunity Based on the Conserved Hemagglutinin Stalk Domain and Its Prospects for Universal Influenza Vaccine Development","volume":"2014","author":"Khanna","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40265-018-0958-7","article-title":"Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine","volume":"78","author":"Fox","year":"2018","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rak, A., Isakova-Sivak, I., and Rudenko, L. (2023). Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines. Vaccines, 11.","DOI":"10.3390\/vaccines11121747"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"N\u00e6ss, L.M., Vanderven, H., Bryant-Bratlie, D., Laake, I., Pleguezuelos, O., and Oftung, F. (2025). FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans. Vaccines, 13.","DOI":"10.3390\/vaccines13111084"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a universal influenza vaccine: Different approaches for one goal","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lopez, C.E., and Legge, K.L. (2020). Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine. Vaccines, 8.","DOI":"10.3390\/vaccines8030434"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bullard, B.L., and Weaver, E.A. (2021). Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9030257"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2018.03.020","article-title":"Toward universal influenza virus vaccines: From natural infection to vaccination strategy","volume":"53","author":"Zhao","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kim, E., Han, G.Y., and Nguyen, H. (2017). An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice. Viruses, 9.","DOI":"10.3390\/v9080234"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhao, T., Wang, L., Li, M., Sun, C., and Shu, Y. (2022). Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1014122"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41563-022-01452-6","article-title":"Towards a universal flu vaccine","volume":"22","year":"2023","journal-title":"Nat. Mater."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Madsen, A., and Cox, R.J. (2020). Prospects and Challenges in the Development of Universal Influenza Vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8030361"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/aje\/kwy145","article-title":"Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo","volume":"187","author":"Epstein","year":"2018","journal-title":"Am. J. Epidemiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1126\/scitranslmed.ade4790","article-title":"An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults","volume":"15","author":"Widge","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"126408","DOI":"10.1016\/j.vaccine.2024.126408","article-title":"Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact","volume":"42","author":"Taaffe","year":"2024","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Qiu, X., Duvvuri, V.R., and Bahl, J. (2019). Computational Approaches and Challenges to Developing Universal Influenza Vaccines. Vaccines, 7.","DOI":"10.3390\/vaccines7020045"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza infection in humans\u2014On the path to a universal vaccine?","volume":"25","author":"Li","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2017.02.009","article-title":"Universal influenza virus vaccines and therapeutic antibodies","volume":"23","author":"Nachbagauer","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.it.2023.11.001","article-title":"Targeting neuraminidase: The next frontier for broadly protective influenza vaccines","volume":"45","author":"Wu","year":"2023","journal-title":"Trends Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Clemens, E., van de Sandt, C., Wong, S., Wakim, L., and Valkenburg, S. (2018). Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. Vaccines, 6.","DOI":"10.3390\/vaccines6020018"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1586\/14760584.2015.1060860","article-title":"Universal influenza vaccines, science fiction or soon reality?","volume":"14","author":"Altenburg","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"McMillan, C.L.D., Young, P.R., Watterson, D., and Chappell, K.J. (2021). The Next Generation of Influenza Vaccines: Towards a Universal Solution. Vaccines, 9.","DOI":"10.3390\/vaccines9010026"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.11.005","article-title":"Broadly protective influenza vaccines: Design and production platforms","volume":"34","author":"Elbahesh","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiy703","article-title":"How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines","volume":"219","author":"Rudraraju","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_56","unstructured":"AVIR Green Hills Biotechnology AG (2009). Randomized, Double-Blind, Placebo-Controlled, Phase I Dose-Escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01), National Library of Medicine."},{"key":"ref_57","unstructured":"AVIR Green Hills Biotechnology AG (2011). Dose Finding Study of Single Dose GHB11L1 in Healthy Adults (GHB-CS07), National Library of Medicine."},{"key":"ref_58","unstructured":"AVIR Green Hills Biotechnology AG (2014). Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults, National Library of Medicine."},{"key":"ref_59","unstructured":"AVIR Green Hills Biotechnology AG (2018). Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults, National Library of Medicine."},{"key":"ref_60","unstructured":"PepTcell Limited (2010). Phase 1b Influenza Vaccine Study in Healthy Subjects, National Library of Medicine."},{"key":"ref_61","unstructured":"PepTcell Limited (2012). Influenza Vaccine Challenge Study in Healthy Subjects, National Library of Medicine."},{"key":"ref_62","unstructured":"PepTcell Limited (2020). A Randomised, Double-Blind, Placebo-Controlled Phase IIb Trial to Test FLU-v Vaccine, National Library of Medicine."},{"key":"ref_63","unstructured":"PepTcell Limited (2020). Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model, National Library of Medicine."},{"key":"ref_64","unstructured":"NIAID (2022). Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults, National Library of Medicine."},{"key":"ref_65","unstructured":"NIAID (2023). Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults, National Library of Medicine."},{"key":"ref_66","unstructured":"NIAID (2025). A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults, National Library of Medicine."},{"key":"ref_67","unstructured":"NIAID (2025). First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared with a Licensed Inactivated Seasonal QIV in Healthy Adults, National Library of Medicine."},{"key":"ref_68","unstructured":"NIAID (2026). BPL-1357 Against H1N1 Influenza Virus Challenge, National Library of Medicine."},{"key":"ref_69","unstructured":"NIAID (2026). Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) with and Without ALFQ Adjuvant in Healthy Adults, National Library of Medicine."},{"key":"ref_70","unstructured":"NIAID (2026). H1ssF Flu Vaccine Clinical Trial, National Library of Medicine."},{"key":"ref_71","unstructured":"NIAID (2025). Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine, National Library of Medicine."},{"key":"ref_72","unstructured":"NIAID (2026). Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults, National Library of Medicine."},{"key":"ref_73","unstructured":"Osivax (2022). Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects, National Library of Medicine."},{"key":"ref_74","unstructured":"Osivax (2022). Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18\u201365 Years, National Library of Medicine."},{"key":"ref_75","unstructured":"Osivax (2023). Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers, National Library of Medicine."},{"key":"ref_76","unstructured":"Osivax (2024). Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers, National Library of Medicine."},{"key":"ref_77","unstructured":"Osivax (2024). Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects, National Library of Medicine."},{"key":"ref_78","unstructured":"Osivax (2025). Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480 \u03bcg, National Library of Medicine."},{"key":"ref_79","unstructured":"Osivax (2025). Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered with OVX836, National Library of Medicine."},{"key":"ref_80","unstructured":"University of Oxford (2014). A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1, National Library of Medicine."},{"key":"ref_81","unstructured":"University of Oxford (2015). A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1, National Library of Medicine."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Groth, N., Bruhwyler, J., Tourneur, J., Piat, E., Moris, P., Le Vert, A., and Nicolas, F. (2025). Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix\u00ae Tetra, a Seasonal Hemagglutinin-Based Vaccine. Vaccines, 13.","DOI":"10.3390\/vaccines13060558"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4161\/hv.7.1.14925","article-title":"A universal influenza vaccine: Where are we in the pursuit of this \u201cHoly Grail\u201d?","volume":"7","author":"Rudolph","year":"2011","journal-title":"Hum. Vaccines"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14760584.2018.1541408","article-title":"Universal influenza vaccines: From viruses to nanoparticles","volume":"17","author":"Wang","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Wang, L., Xie, Q., Yu, P., Zhang, J., He, C., Huang, W., Wang, Y., and Zhao, C. (2025). Research Progress of Universal Influenza Vaccine. Vaccines, 13.","DOI":"10.3390\/vaccines13080863"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sayedahmed, E.E., Elshafie, N.O., Santos, A.P., Jagannath, C., Sambhara, S., and Mittal, S.K. (2024). Development of NP-Based Universal Vaccine for Influenza A Viruses. Vaccines, 12.","DOI":"10.3390\/vaccines12020157"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/M19-0735","article-title":"Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults","volume":"172","author":"Pleguezuelos","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"van Doorn, E., Pleguezuelos, O., Liu, H., Fernandez, A., Bannister, R., Stoloff, G., Oftung, F., Norley, S., Huckriede, A., and Frijlink, H.W. (2017). Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: Study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2341-9"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41467-026-70396-1","article-title":"A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1\/2a study","volume":"17","author":"Hertoghs","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41541-023-00772-1","article-title":"Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen","volume":"8","author":"Swart","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1021\/acsinfecdis.8b00206","article-title":"A Perspective on Nanoparticle Universal Influenza Vaccines","volume":"4","author":"Deng","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"McCraw, D.M., Myers, M.L., Gulati, N.M., Prabhakaran, M., Brand, J., Andrews, S., Gallagher, J.R., Maldonado-Puga, S., Kim, A.J., and Torian, U. (2023). Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011514"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1039\/D2AY01890J","article-title":"Development and validation of a mass spectrometry based analytical method to quantify the ratios in hemagglutinin trimers in quadrivalent influenza nanoparticle vaccine\u2014FluMos-v1","volume":"15","author":"Shajahan","year":"2023","journal-title":"Anal. Methods"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1038\/s41598-024-54876-2","article-title":"Mosaic quadrivalent influenza vaccine single nanoparticle characterization","volume":"14","author":"Yang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"105505","DOI":"10.1016\/j.antiviral.2022.105505","article-title":"The race toward a universal influenza vaccine: Front runners and the future directions","volume":"210","author":"Hu","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"102594","DOI":"10.1016\/j.omtn.2025.102594","article-title":"A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets","volume":"36","author":"Wang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jacobs, B., Leroux-Roels, I., Bruhwyler, J., Groth, N., Waerlop, G., Janssens, Y., Tourneur, J., De Boever, F., Alhatemi, A., and Moris, P. (2024). Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults. Vaccines, 12.","DOI":"10.3390\/vaccines12121391"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"ofad500.442","DOI":"10.1093\/ofid\/ofad500.442","article-title":"372. Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical trial","volume":"10","author":"Willems","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Leroux-Roels, I., Waerlop, G., Tourneur, J., De Boever, F., Maes, C., Bruhwyler, J., Guyon-Gellin, D., Moris, P., Del Campo, J., and Willems, P. (2022). Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.852904"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1473-3099(23)00351-1","article-title":"Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"23","author":"Willems","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Xu, L., Ren, W., Wang, Q., and Li, J. (2024). Advances in Nucleic Acid Universal Influenza Vaccines. Vaccines, 12.","DOI":"10.3390\/vaccines12060664"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ijbiomac.2022.12.066","article-title":"Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic\/pandemic preparedness","volume":"226","author":"Rcheulishvili","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"25045","DOI":"10.1021\/acsnano.3c07669","article-title":"Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform","volume":"17","author":"Park","year":"2023","journal-title":"ACS Nano"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"eadc9937","DOI":"10.1126\/sciadv.adc9937","article-title":"A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets","volume":"8","author":"Lanfermeijer","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"ofae631.792","DOI":"10.1093\/ofid\/ofae631.792","article-title":"P-594. Temperature Stability of BPL-1357, a BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","volume":"12","author":"Banerjee","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Cnossen, V.M., Moreira, P.C.L., Engelhardt, O.G., Samolej, J., Groeneveld, G.H., Jochems, S.P., Huisman, W., Pedersen, G.K., W\u00f8rzner, K., and Recek, L. (2025). Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: The FLUniversal consortium. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1568778"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"ofae631.188","DOI":"10.1093\/ofid\/ofae631.188","article-title":"593. Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","volume":"12","author":"Han","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Taaffe, J., Lambach, P., Gsell, P., Ghiga, I., and Goldin, S. (2025). Next-Generation Influenza Vaccines and the Pandemic Horizon: Challenges, Innovations, and the Road Ahead. Vaccines, 13.","DOI":"10.3390\/vaccines13111097"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"eabd3601","DOI":"10.1126\/scitranslmed.abd3601","article-title":"Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans","volume":"12","author":"Dugan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.chom.2019.02.009","article-title":"Original Antigenic Sin: Friend or Foe in Developing a Broadly Cross-Reactive Vaccine to Influenza?","volume":"25","author":"Devarajan","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From Original Antigenic Sin to the Universal Influenza Virus Vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Steventon, R., Stolle, L., and Thompson, C.P. (2025). How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza. Antibodies, 14.","DOI":"10.3390\/antib14010004"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to influenza virus neuraminidase: An independent correlate of protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/eri.11.51","article-title":"Serologic assays for influenza surveillance, diagnosis and vaccine evaluation","volume":"9","author":"Katz","year":"2011","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e02332-17","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e00417-16","DOI":"10.1128\/mBio.00417-16","article-title":"Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model","volume":"7","author":"Memoli","year":"2016","journal-title":"mBio"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.virol.2018.03.013","article-title":"Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin","volume":"518","author":"Korenkov","year":"2018","journal-title":"Virology"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Isakova-Sivak, I., Matyushenko, V., Kotomina, T., Kiseleva, I., Krutikova, E., Donina, S., Rekstin, A., Larionova, N., Mezhenskaya, D., and Sivak, K. (2019). Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge. Vaccines, 7.","DOI":"10.3390\/vaccines7030061"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/infdis\/jiz044","article-title":"Dynamic Perspectives on the Search for a Universal Influenza Vaccine","volume":"219","author":"McDermott","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1017\/S0950268821002284","article-title":"Modelling the impact of universal influenza vaccines on seasonal influenza with different subtypes","volume":"149","author":"Li","year":"2021","journal-title":"Epidemiol. Infect."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1750-2659.2011.00288.x","article-title":"The potential economic value of a \u201cuniversal\u201d (multi-year) influenza vaccine","volume":"6","author":"Lee","year":"2011","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1016\/j.vaccine.2023.08.031","article-title":"The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis","volume":"41","author":"Waterlow","year":"2023","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"201909613","DOI":"10.1073\/pnas.1909613116","article-title":"Future epidemiological and economic impacts of universal influenza vaccines","volume":"116","author":"Sah","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1016\/j.vaccine.2021.06.072","article-title":"Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice","volume":"39","author":"Lo","year":"2021","journal-title":"Vaccine"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Jazayeri, S.D., and Poh, C.L. (2019). Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins. Vaccines, 7.","DOI":"10.3390\/vaccines7040169"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4049\/jimmunol.1801054","article-title":"Development of a Universal Influenza Vaccine","volume":"202","author":"Estrada","year":"2019","journal-title":"J. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Viboud, C., Gostic, K., Nelson, M.I., Price, G.E., Perofsky, A., Sun, K., Trov\u00e3o, N.S., Cowling, B.J., Epstein, S.L., and Spiro, D.J. (2020). Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008583"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1016\/j.vaccine.2019.06.080","article-title":"Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity","volume":"37","author":"Innis","year":"2019","journal-title":"Vaccine"},{"key":"ref_132","first-page":"1798","article-title":"Will the public take a universal influenza vaccine?: The need for social and behavioral science research","volume":"16","author":"Jamison","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/irv.12963","article-title":"The economic burden of influenza among adults aged 18 to 64: A systematic literature review","volume":"16","author":"Courville","year":"2022","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2511132","DOI":"10.1080\/22221751.2025.2511132","article-title":"Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses","volume":"14","author":"Huang","year":"2025","journal-title":"Emerg. Microbes Infect."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1038\/s41467-024-47862-9","article-title":"Seasonal antigenic prediction of influenza A H3N2 using machine learning","volume":"15","author":"Syed","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Steventon, R., Lee, M., Gregory, R., Stolle, L., McInally, C., Jarvis, L., Robb, N.C., Carnell, G., Temperton, N., and Cherny, S. (2026). Antigenic seniority and convergent haemagglutinin evolution shaped the immune landscape preceding influenza B\/Yamagata\u2019s extinction. medRxiv.","DOI":"10.2139\/ssrn.6794361"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","article-title":"Broadly neutralizing antibodies target a haemagglutinin anchor epitope","volume":"602","author":"Guthmiller","year":"2021","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5691673","DOI":"10.1155\/2024\/5691673","article-title":"Antibody Response to Influenza Hemagglutinin Conserved Stalk Domain after Sequential Immunization with Old Vaccine Strains","volume":"2024","author":"Kongchanagul","year":"2024","journal-title":"Adv. Virol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Hwang, H.S., Chang, M., and Kim, Y.A. (2020). Influenza\u2013Host Interplay and Strategies for Universal Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8030548"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, M., Misplon, J.A., Price, G.E., Lo, C.Y., and Epstein, S.L. (2016). Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153195"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12250-020-00283-6","article-title":"Flu Universal Vaccines: New Tricks on an Old Virus","volume":"36","author":"Du","year":"2020","journal-title":"Virol. Sin."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e0045325","DOI":"10.1128\/jvi.00453-25","article-title":"Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins","volume":"99","author":"Dzimianski","year":"2025","journal-title":"J. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7774\/cevr.2013.2.2.71","article-title":"Toward a universal influenza vaccine: From the perspective of protective efficacy","volume":"2","author":"Jang","year":"2013","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/17460441.2020.1801629","article-title":"Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection","volume":"15","author":"Jang","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.chom.2018.06.016","article-title":"Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine","volume":"24","author":"Coughlan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.it.2011.08.007","article-title":"Targeting B cell responses in universal influenza vaccine design","volume":"32","author":"Kaur","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Kumar, A., Meldgaard, T.S., and Bertholet, S. (2018). Novel Platforms for the Development of a Universal Influenza Vaccine. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00600"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/4\/75\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:24:00Z","timestamp":1786440240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/4\/75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":147,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antib15040075"],"URL":"https:\/\/doi.org\/10.3390\/antib15040075","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}